In hyperosmolar hyperglycemic state (HHS) managed with intravenous fluids but without insulin, is a dextrose infusion required?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 9, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Dextrose Infusion in HHS Without Insulin

Yes, dextrose infusion is required in HHS when glucose falls below 14 mmol/L (250 mg/dL), even if insulin has not yet been started. This prevents hypoglycemia and allows continued fluid resuscitation while osmolality normalizes.

The Critical Timing Issue

In HHS managed initially with fluids alone (without insulin), the glucose will fall significantly from fluid replacement itself. When glucose drops to <14 mmol/L, you must start 5% or 10% dextrose infusion alongside the 0.9% saline 1. This is essential because:

  • Fluid therapy alone causes substantial glucose reduction through dilution and improved renal perfusion
  • The target glucose range during HHS treatment is 10-15 mmol/L in the first 24 hours 1
  • Without dextrose supplementation, glucose may fall too rapidly, creating dangerous osmotic shifts

The Fluid-First Approach Context

The most recent guidelines explicitly state that insulin should be withheld until glucose stops falling with fluid administration alone (unless ketonaemia is present) 2, 1. This approach recognizes that:

  • Fluid replacement is the primary intervention in HHS
  • Early insulin use may be detrimental 3
  • Glucose often falls from 30+ mmol/L to <14 mmol/L with fluids alone

When to Start Dextrose

Start 5% or 10% glucose infusion when blood glucose reaches <14 mmol/L 1. At this point:

  • Continue 0.9% saline for volume replacement
  • Add dextrose to prevent hypoglycemia
  • Maintain glucose between 10-15 mmol/L for the first 24 hours
  • This allows continued osmolality correction (target 3-8 mOsm/kg/h reduction) without risking hypoglycemia 1

The Target Glucose Range

Unlike DKA where glucose targets are 150-200 mg/dL (8.3-11.1 mmol/L), HHS targets are higher at 200-250 mg/dL (11.1-13.9 mmol/L) until resolution 2. However, once glucose falls below 14 mmol/L during the fluid resuscitation phase, dextrose prevents further decline while osmolality continues to normalize.

Common Pitfall

The major error is assuming that because insulin hasn't been started, dextrose isn't needed. Fluid therapy alone can drop glucose precipitously in HHS, and without dextrose supplementation at <14 mmol/L, you risk:

  • Hypoglycemia
  • Too-rapid osmolality changes (>8 mOsm/kg/h)
  • Increased risk of cerebral edema and central pontine myelinolysis 1, 3

Bottom line: Dextrose infusion is mandatory when glucose <14 mmol/L in HHS, regardless of whether insulin has been initiated.

Related Questions

What is the recommended blood glucose target range during treatment of hyperosmolar hyperglycaemic state (HHS)?
In a patient with hyperosmolar hyperglycemic state whose glucose decreased from 33 mmol/L to 22 mmol/L after receiving 0.9% normal saline at 1 L/hour for 2 hours, with serum sodium unchanged at 132 mEq/L, what is the most appropriate next step in fluid management?
Can Hyperosmolar Hyperglycemic State (HHS) present with alkalosis, specifically a Venous Blood Gas (VBG) pH of 7.55?
What is an emergency checklist for diagnosing and managing hyperosmolar hyperglycemic state, including glucose and serum osmolarity criteria, fluid resuscitation, potassium replacement, insulin titration, monitoring frequency, and precautions according to British Diabetes Society guidelines?
Which initial fluid therapy regimen is appropriate for a 72-year-old type 2 diabetic with normal renal function presenting with hyperosmolar coma, severe hyperglycemia, and low‑normal serum potassium?
How should symptomatic adenomyosis be managed in a reproductive‑age woman?
In a 64-year-old man with de novo low-volume metastatic hormone-sensitive prostate cancer receiving continuous androgen deprivation therapy (ADT) plus enzalutamide, who has undetectable PSA after 20 months but significant fatigue, hot flashes, decreased libido, and cognitive slowing, what does the current evidence indicate regarding intermittent versus continuous therapy?
When will prednisone begin to reduce inflammation and relieve symptoms?
What is the recommended management for a patient with mixed connective tissue disease, lupus nephritis, and Sjögren's syndrome?
What is the appropriate weight‑based dosing of piperacillin‑tazobactam (Zosyn)?
Can intrauterine devices (copper IUD and levonorgestrel-releasing hormonal IUD) be used safely during breastfeeding?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.